1. A digitally printable polymer coated paper or board, the paper or board having a top and a bottom surface, wherein the top surface of the paper or board contains no additional structure and has at least one extruded wax free coating layer directly adhering to the paper or board, said coating layer comprising an electrically chargeable polymer selected from a group consisting of ethylene methyl acrylate copolymer (EMA), ethylene ethyl acrylate copolymer (EEA), and ethylene butyl acrylate copolymer (EBA), and the polymer coated top surface of the paper or board being a non-irregular surface which is digitally printable.
2. The paper or board of claim 1, wherein the at least one coating layer comprises ethylene methyl acrylate copolymer (EMA).
3. The paper or board of claim 2, wherein both top and bottom surfaces of the paper or board are coated with a coating layer comprising ethylene methyl acrylate copolymer (EMA).
4. The paper or board of claim 3, wherein the ethylene methyl acrylate copolymer (EMA) further comprises methyl acrylate monomer.
5. The paper or board of claim 4, wherein the methyl acrylate monomer comprises from about 9 mole percent to about 20 mole percent.
6. The paper or board of claim 5, wherein the methyl acrylate monomer comprises from about 15 mole percent to about 20 mole percent.
7. The paper or board of claim 1, wherein the board is packaging board and a weight of the packaging board is about 130 gm2 to about 500 gm2.
8. The paper or board of claim 7, wherein a weight of the packaging board is about 170 gm2 to about 300 gm2.
9. The paper or board of claim 1, wherein a weight of the paper is about 20 gm2 to about 130 gm2.
10. The paper or board of claim 9, wherein a weight of the paper is about 40 gm2 to about 120 gm2.
11. The paper or board of claim 2, wherein a weight of the ethylene methyl acrylate copolymer coating layer is about 7 gm2 to about 20 gm2.
12. The paper or board of claim 1, wherein ethylene methyl acrylate (EMA) copolymer is an electrically chargeable coating layer.
13. The paper or board of claim 12, wherein ethylene methyl acrylate copolymer comprises the sole coating layer of the paper or board.
14. The paper or board of claim 13, wherein substantially pure ethylene methyl acrylate copolymer comprises the sole coating layer.
15. A method of digital printing utilizing digitally printable polymer coated paper or board of claim 1, the method comprising the steps of:
providing the coated paper or board of claim 1;
wherein the coating contains electrically chargeable acrylate copolymer of ethylene;
electrically charging a surface of the paper or board;
transferring toner particles to the surface of the paper or board by way of an electric field,
wherein the toner particles form a print image; and
directing infrared radiation to the toner particles on the paper or board surface thereby heat fusing the toner particles to the polymer coating.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
What is claimed is:
1. A method for minimizing the toxic effects of chemotherapeutic agents or cytotoxic irradiation on the hematopoietic cells of a patient having neoplastic cells or a malignant tumor, comprising the steps of:
A. treating the patient with a dosage of at least one hematopoietic cell stimulating factor, the dosage being sufficient in amount and time to cause a substantial increase in the population of the hematopoietic cells and in differentiated blood cells, and
B. treating the patient with a dosage of chemotherapeutic agents or cytotoxic irradiation sufficient to substantially reduce the population of neoplastic cells.
2. The method of claim 1, wherein Step B is initiated after the cessation of Step A.
3. The method of claim 1, wherein Step B is initiated before the cessation of Step A.
4. The method of claim 1, wherein after Step A and before Step B, further comprising Step C, allowing a sufficient amount of time to elapse so that the hematopoietic cells enter a state of post-mitotic quiescence.
5. The method of claim 1, wherein Step A is performed for a sufficient period of time to stimulate the hematopoietic cells to enter a phase of proliferative activity sufficient to produce a crest in the population of the hematopoietic cells.
6. The method of claim 1, wherein the at least one hematopoietic cell stimulating factor is a cytokine, hematopoietic growth factor, fusion protein having functional domains of any of the cytokines or hematopoietic growth factors, or an agonist of any of the cytokines or hematopoietic growth factors.
7. The method of claim 6, wherein the cytokine or hematopoietic growth factor is one or more selected from the group consisting of Colony Stimulating Factors, Interleukins, Interferons, Tumor Necrosis Factor, Erythropoietin, and Thrombopoietin,
8. The method of claim 7 wherein the Colony Stimulating Factors are one or more from the group consisting of Granulocyte Macrophage Colony Stimulating Factor, Macrophage Colony Stimulating Factor and Granulocyte Colony Stimulating Factor.
9. The method of claim 7 wherein the Interleukins are one or more selected from the group consisting of IL-1, IL-2, IL-3, IL-6, IL-6, IL-11 and IL-12.
10. The method of claim 1, wherein Step B is performed while the hematopoietic cells are in a state of post-mitotic quiescence.
11. The method of claim 1, used to treat one or more cancers from the group consisting of lymphomas, Hodgkins disease, Wilm’s tumor, embryonal rhabdomyosarcoma, small cell lung cancer, central nervous system lymphoma, anal carcinoma, bladder carcinoma, breast cancer, laryngeal cancer, osteogenic sarcoma, soft tissue sarcomas, nonsmall cell lung cancer, breast cancer, nasopharyngeal cancer, other cancers of the head and neck region, pancreatic cancer, gastric carcinoma, prostate cancer, and cervical carcinoma.
12. The method of claim 1, wherein the chemotherapeutic drugs are one or more substances selected from the following groups: alkylating agents which interfere with the nucleic acid or protein metabolism of dividing cells, topoisomerase inhibitors, drugs that interfere with DNA synthesis, drugs that interfere with synthesis and assembly of microtubules or the mitotic spindle apparatus, and antibiotics.
13. The method of claim 10, wherein the alkylating agents are one or more selected from the group consisting of Cyclophosphamide, Busalfan, Ifosfamide, Procarbazine, Dacarbazine, Temozolomide, Hexamethylmelamine, and ThioTEPA.
14. The method of claim 10, wherein the topoisomerase inhibitors are one or more from the group consisting of Etoposide, Doxo-rubicin Epirubicin and, Amonafide.
15. The method of claim 10, wherein the antibiotics are one or more selected from the group consisting of Mitomycin C, and Actinomysin D.
16. The method of claim 10, wherein the drugs that interfere with DNA synthesis are one or more selected from the group consisting of Cytosine Arabnoside, Mercaptopurine, Methotrexate, Fluorouracil, Carboplatin, Oxaliplatin, JM216, CI-973, DWA 2114R, JM335, Bisplatinum and analogues thereof.
17. The method of claim 10, wherein the drugs that interfere with synthesis and assembly of microtubules and the mitotic spindle apparatus, are one or more selected from the group consisting of Vincristine and Paclitaxel.